Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04718792
PHASE2

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

Sponsor: Anders Fink-Jensen, MD, DMSci

View on ClinicalTrials.gov

Summary

The purpose of this project is to assess the feasibility and safety of administering a single dose of psilocybin to patients diagnosed with alcohol use disorder (AUD). In addition the investigators will establish the pharmacokinetic properties of the active metabolite psilocin. This is the first step in a research project that has the overall aim to evaluate the efficacy of a single administration of psilocybin as an intervention for treatment of AUD.

Key Details

Gender

All

Age Range

20 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2023-02-09

Completion Date

2024-07-21

Last Updated

2024-07-12

Healthy Volunteers

No

Interventions

DRUG

Psilocybin

A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)

Locations (1)

Psychiatric Center Copenhagen

Copenhagen, Frederiksberg, Denmark